发明授权
- 专利标题: LHRH-antagonists in the treatment of fertility disorders
- 专利标题(中): LHRH拮抗剂治疗生育障碍
-
申请号: US10661780申请日: 2003-09-15
-
公开(公告)号: US07393834B2公开(公告)日: 2008-07-01
- 发明人: Philippe Bouchard , Rene Frydman , Paul Devroey , Klaus Diedrich , Jurgen Engel
- 申请人: Philippe Bouchard , Rene Frydman , Paul Devroey , Klaus Diedrich , Jurgen Engel
- 申请人地址: DE Frankfurt
- 专利权人: AEterna Zentaris GmbH
- 当前专利权人: AEterna Zentaris GmbH
- 当前专利权人地址: DE Frankfurt
- 代理机构: Pillsbury Winthrop Shaw Pittman LLP
- 主分类号: A61K38/09
- IPC分类号: A61K38/09 ; A61K31/551 ; A61K31/4743
摘要:
A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.
公开/授权文献
- US20050049200A1 LHRH-antagonists in the treatment of fertility disorders 公开/授权日:2005-03-03